{"id":"W4406470071","doi":"10.1186/s13045-024-01657-z","title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Foghorn Therapeutics; Celgene; Jazz Pharmaceuticals; Leukemia and Lymphoma Society; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer","keywords":"Medicine; Refractory (planetary science); Open label; Myeloid leukemia; Azacitidine; Hematology; Internal medicine; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001531726,0.0003579203,0.002187045,0.001570788,0.0001488882,0.0000307332,0.0006172684,0.0006391896,0.00009656775],"category_scores_gemma":[0.001467536,0.0002340533,0.00006673762,0.001296395,0.0004291396,0.0004941925,0.0002359522,0.002469825,0.000007808353],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003590076,"about_ca_system_score_gemma":0.008303762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001771519,"about_ca_topic_score_gemma":0.0005412014,"domain_scores_codex":[0.9957554,0.0007740812,0.001725832,0.0004894797,0.0005614343,0.0006937856],"domain_scores_gemma":[0.9959803,0.001406624,0.001064523,0.0004342701,0.0008235627,0.0002906768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8699432,0.01976846,0.06563333,0.0002364044,0.001480851,0.01606828,0.0008000924,0.00003945975,0.01080109,0.000563269,0.009615859,0.00504969],"study_design_scores_gemma":[0.8978836,0.0564022,0.0291921,0.001782762,0.0007015934,0.003804269,0.0007603135,0.0004280939,0.002967677,0.0002125729,0.005485578,0.0003792321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989263,0.0001639778,0.00009829929,0.00670851,0.0002683962,0.002476152,0.0000140294,0.00001812133,0.0009895407],"genre_scores_gemma":[0.9912068,0.0002015708,0.00666461,0.0009012588,0.0000504606,0.0001262694,0.00005885852,0.00004473185,0.0007454844],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03663374,"threshold_uncertainty_score":0.9998315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04688349364955659,"score_gpt":0.3858644542352145,"score_spread":0.338980960585658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}